PBS dispute could leave MS patients with huge bills for crucial drugs Ocrevus and Kesimpta
A dispute over how Australia prices medicines has sparked fears 10,000 people with multiple sclerosis will be forced…
Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU)
Statistically significant and clinically meaningful results seen in RemIND trial with complete responses achieved in 3 CIndU types1Remibrutinib,…
Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery
New facility will enable end‑to‑end discovery across key disease areas and technology platforms, joining existing global research sites…
One in four Indians faces silent genetic threat to heart health, shows study
In the Asia Pacific and Middle East region, two in three individuals (66%) skip routine heart tests, while…
Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease
Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global phase III…